Assessing Efficacy and the Speed of Response in Psoriasis Treatment

Light, Jeremy G.; Haidari, Wasim; Feldman, Steven R.

doi:10.1080/09546634.2019.1643588

Cited by 3 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drugs generally possess a concentration-response-curve to behave in therapies (Satoh et al, 2013 ; Fernando & Soysa, 2015 ; Light et al, 2019 ). In this case, the bee venom treatment ability to inhibit ROS and MDA level does not increase linear as concentration of melittin increases in the brain and blood plasma.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic improvement provided by microneedle patch in delivering bee venom, a case study in combating scopolamine-induced neurodegeneration in mouse model

Nguyen

Yoo

An³

et al. 2022

Drug Delivery

View full text Add to dashboard Cite

Much research has shown Bee venom to be an effective neuroprotective agent. However, the usual transdermal injection of bee venom poses many pharmacokinetic disadvantages. Here, we compared the administration of bee venom via subcutaneous injection (SC) and via Microneedle patch (MN). Both administrated routes produce significant recovery effects, however: the MN significantly prolongs the bio-significant-and-yet-lower concentration of bee venom in mice bodies. In contrast, SC could produce only a short period of much higher bee venom levels in the blood and brain. We also see that due to the concentration-response-curve of bee venom (represented by melittin): mice bodies do not require much higher bee venom concentration (seen in the SC group) to produce a much more significant neuroprotective effect (than seen in those treated with the MN method). Therefore, a MN could maintain bee venom levels in mice bodies at lower-yet-more-efficient concentrations. This is important, as bee venom can cause more adverse effects and pain sensations, at higher concentrations. For the first time, we confirmed that the pharmacokinetic advantages of MN delivered bee venom also guarantee a holistic neuroprotection effect (which was shown by SC delivered bee venom in previous research). This was proven via the results of the water maze experiments for long-term learning memory assessment and protein analysis of key neuronal regulatory proteins: BDNF, p-CREB, iNOS, and mArhR 1. In conclusion, for situations where we ought to administrate drugs at a more downward amount, such as bee venom, MN can keep the therapeutic concentrations at a lower, yet interestingly, more-efficient level.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic improvement provided by microneedle patch in delivering bee venom, a case study in combating scopolamine-induced neurodegeneration in mouse model

Nguyen

Yoo

An³

et al. 2022

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Analysis of response-over-time curves in ECLIPSE reveals that secukinumab achieved a faster onset of response through week 16, but after week 20 the efficacy favored guselkumab which was maintained through one year. 46 Ixekizumab, another anti-IL-17 antibody, was faster acting than guselkumab in IXORA-R, but the two drugs were equally effective at week 24; relative efficacy at longer times was not evaluated. 24 …”

Section: Discussionmentioning

confidence: 99%

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis

Light¹,

Su²,

Feldman³

2021

CCID

Self Cite

View full text Add to dashboard Cite

“…Another means of determining the speed of onset is to analyze the time required for 50% of patients to achieve a predetermined level of success, for example PASI 75 or 90 response, denoted as PASI 75 50 and PASI 90 50 , respectively, which can be compared across various biologic agents. 14 Numerous clinical trials focus on comparing the overall efficacy of various biologic agents. However, speed of onset of a biologic therapy is a less emphasized but also important factor to consider when initiating therapy, particularly for patients with acute onset of severe or debilitating disease.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials

Johnson

Heron

Ghamrawi

et al. 2021

Journal of Psoriasis and Psoriatic Arthritis

Self Cite

View full text Add to dashboard Cite

Background: Clinical trials often focus on the efficacy of biologic agents in the treatment of psoriasis without emphasis on the speed of response. Objective: We evaluated clinical trial data to determine which biologic agents achieve the fastest treatment response. Methods: A review of phase III clinical trials of biologic agents in psoriasis was performed. Speed was determined by analyzing Psoriasis Area and Severity Index (PASI) 75/90 responder curves to estimate the point at which 50% of subjects achieved that outcome, PASI 75/9050. Time to achieve PASI 75/9050 was averaged across trials. Results: Time to achieve PASI 7550, in weeks: brodalumab 210 mg, 3.5; ixekizumab 80 mg Q2 W, 4; secukinumab 300 mg, 5; infliximab 5mg/kg, 5.5; risankizumab 150 mg, 6; guselkumab 100 mg, 6.25; adalimumab 40 mg, 7.25; ustekinumab 45/90 mg, 7.4; certolizumab 400 mg, 7.5; tildrakizumab 100 mg, 9; etanercept 50 mg, 12.5. PASI 9050 responder rate estimations revealed a similar trend. Conclusion: Interleukin-17 inhibitors have a more rapid treatment response compared with other classes. Although speed is important, efficacy, persistence, side effects, cost of treatment, and number of injections are all factors to consider.

show abstract

Assessing Efficacy and the Speed of Response in Psoriasis Treatment

Cited by 3 publications

References 1 publication

Pharmacokinetic improvement provided by microneedle patch in delivering bee venom, a case study in combating scopolamine-induced neurodegeneration in mouse model

Pharmacokinetic improvement provided by microneedle patch in delivering bee venom, a case study in combating scopolamine-induced neurodegeneration in mouse model

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis

Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials

Contact Info

Product

Resources

About